AR099353A1 - Composiciones de triglicéridos y usos de las mismas - Google Patents

Composiciones de triglicéridos y usos de las mismas

Info

Publication number
AR099353A1
AR099353A1 ARP140104294A ARP140104294A AR099353A1 AR 099353 A1 AR099353 A1 AR 099353A1 AR P140104294 A ARP140104294 A AR P140104294A AR P140104294 A ARP140104294 A AR P140104294A AR 099353 A1 AR099353 A1 AR 099353A1
Authority
AR
Argentina
Prior art keywords
solid composition
solid
group
triglycerides
acids
Prior art date
Application number
ARP140104294A
Other languages
English (en)
Inventor
Kakkis Emil
Morris Gabrielle
Klopp John
Jungles Steven
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of AR099353A1 publication Critical patent/AR099353A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición sólida caracterizada porque comprende triglicéridos con uno o más ácidos grasos como un ingrediente activo y una sustancia sólida; en donde el ingrediente activo tiene una pureza mayor que el 95% y la composición sólida comprende al menos aproximadamente el 50% en peso de triglicéridos. Reivindicación 4: La composición sólida de la reivindicación 1 caracterizada por que el o los ácidos grasos son uno o más ácidos fenilalcanoicos y/o ácidos fenilalquenoicos. Reivindicación 5: La composición sólida de la reivindicación 4 caracterizada por que los triglicéridos comprenden un compuesto de fórmula (1) en donde R¹, R² y R³ son independiente H, el grupo de formulas (2) o el grupo de fórmula (3); y n es cero o un número par de 2 - 24 y m es un número par de 2 - 24, con la condición de que al menos uno de R¹, R² y R³ sea diferente de H. Reivindicación 6: La composición sólida de la reivindicación 5 caracterizada por que el compuesto es fenilbutirato de glicerol. Reivindicación 10: La composición sólida de la reivindicación 8 caracterizada por que el portador sólido se selecciona del grupo que consiste en SiO₂, TiO₂, Al₂O₃, zeolitos, Cab-O-Sil y combinaciones de estos. Reivindicación 11: La composición sólida de cualquiera de las reivindicaciones que anteceden caracterizada por que la sustancia sólida además comprende uno o más polímeros de liberación progresiva.
ARP140104294A 2013-11-14 2014-11-14 Composiciones de triglicéridos y usos de las mismas AR099353A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14

Publications (1)

Publication Number Publication Date
AR099353A1 true AR099353A1 (es) 2016-07-20

Family

ID=53058066

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104294A AR099353A1 (es) 2013-11-14 2014-11-14 Composiciones de triglicéridos y usos de las mismas

Country Status (18)

Country Link
US (3) US20160243071A1 (es)
EP (2) EP3068383B1 (es)
JP (3) JP2017501972A (es)
KR (1) KR102291310B1 (es)
CN (2) CN105764497A (es)
AR (1) AR099353A1 (es)
AU (1) AU2014348470B2 (es)
CA (2) CA3197154A1 (es)
CL (1) CL2016001130A1 (es)
ES (1) ES2833294T3 (es)
IL (1) IL245588B (es)
MX (2) MX2016006329A (es)
MY (1) MY177028A (es)
PE (1) PE20161024A1 (es)
PH (1) PH12016500821A1 (es)
RU (1) RU2016123169A (es)
TW (1) TWI640327B (es)
WO (1) WO2015073816A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160243071A1 (en) * 2013-11-14 2016-08-25 John KLOPP Solid compositions of triglycerides and uses thereof
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
CA3110724A1 (en) 2018-08-27 2020-03-05 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800610B2 (ja) * 1992-12-15 1998-09-21 不二製油株式会社 水中油型乳化物の製造法
JP3522843B2 (ja) * 1994-07-29 2004-04-26 昭和産業株式会社 リポ製剤
AU4858796A (en) 1995-02-07 1996-08-27 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
EP1150579B1 (en) * 1999-02-05 2005-08-31 Baylor Research Institute Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven carbon fatty acid
US8399515B2 (en) * 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
MX338247B (es) * 2004-07-02 2016-04-07 Baylor Res Inst Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
CN101137357B (zh) * 2005-03-10 2012-07-04 3M创新有限公司 含有羟基羧酸的酯的抗微生物组合物
JP2008533048A (ja) * 2005-03-10 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 耳の感染症の治療方法
US20090017118A1 (en) * 2006-02-10 2009-01-15 Sportscom Danmark Aps Coated tablets, their methods of preparation, and related uses
JP5296366B2 (ja) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 医薬品用持久力向上剤および持久力向上用医薬品
US8642012B2 (en) 2008-04-29 2014-02-04 Hyperion Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
CA2801206A1 (en) * 2010-06-14 2011-12-22 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
CN101919453B (zh) * 2010-08-16 2013-04-10 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
CN107271696A (zh) 2011-09-30 2017-10-20 海波龙治疗有限责任公司 氮清除药物的治疗性监测方法
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
EP2838522B1 (en) * 2012-04-16 2024-02-21 University of Pittsburgh - Of the Commonwealth System of Higher Education Phenylbutyrate for the treatment of medium-chain acyl-coa dehydrogenase deficiency
BR112015013349A2 (pt) * 2012-12-13 2017-07-11 Baylor Res Institute At Dallas trieptanoína para o tratamento de deficiência de transportador de glicose 1
US20160243071A1 (en) * 2013-11-14 2016-08-25 John KLOPP Solid compositions of triglycerides and uses thereof

Also Published As

Publication number Publication date
PH12016500821A1 (en) 2016-06-13
ES2833294T3 (es) 2021-06-14
US20160243071A1 (en) 2016-08-25
WO2015073816A1 (en) 2015-05-21
US20230181513A1 (en) 2023-06-15
CN113181158A (zh) 2021-07-30
MX2021001790A (es) 2021-04-19
EP3068383A4 (en) 2017-11-08
EP3068383A1 (en) 2016-09-21
PE20161024A1 (es) 2016-11-10
AU2014348470B2 (en) 2020-01-30
MY177028A (en) 2020-09-02
JP2020111585A (ja) 2020-07-27
KR20160084407A (ko) 2016-07-13
JP2017501972A (ja) 2017-01-19
CN105764497A (zh) 2016-07-13
RU2016123169A (ru) 2017-12-19
TW201609189A (zh) 2016-03-16
AU2014348470A1 (en) 2016-05-26
IL245588A0 (en) 2016-06-30
CA2929688C (en) 2023-06-13
CL2016001130A1 (es) 2017-01-20
JP2022107017A (ja) 2022-07-20
CA3197154A1 (en) 2015-05-21
CA2929688A1 (en) 2015-05-21
EP3782610A1 (en) 2021-02-24
KR102291310B1 (ko) 2021-08-23
MX2016006329A (es) 2016-09-06
US20200069631A1 (en) 2020-03-05
EP3068383B1 (en) 2020-09-16
TWI640327B (zh) 2018-11-11
IL245588B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
CU20210009A7 (es) Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3)
AR121135A2 (es) Solución no acuosa de regulador(es) de crecimiento vegetal y solvente(s) orgánicos polar(es) y/o semi-polar(es)
CO2018002063A2 (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
CL2017002155A1 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
AR099353A1 (es) Composiciones de triglicéridos y usos de las mismas
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP14020586A (es) Composición para el control de plagas que incluye un derivado de iminopiridina novedoso
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
NI201200191A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP13012519A (es) Compuestos sustituidos de benzamida
CR20140195A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas
CL2017000863A1 (es) Composición de activo de suavizante de tejidos
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CO7111275A2 (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CU24078B1 (es) Tres compuestos de sulfonamidas anilladas
UY33415A (es) Composiciones de alcoxicarboxamidas microbiocidas y fungicidas y su preparacion
AR096472A1 (es) Compuestos y composiciones antimicrobianos
AR101077A1 (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
AR090376A1 (es) Compuestos herbicidas

Legal Events

Date Code Title Description
FC Refusal